Skip to main content

Idecabtagene vicleucel Side Effects

Medically reviewed by Drugs.com. Last updated on Aug 14, 2023.

Applies to idecabtagene vicleucel: intravenous suspension.

Warning

Intravenous route (Suspension)

Warning: Cytokine Release Syndrome, Neurologic Toxicities, HLH/MAS, and Prolonged CytopeniaCytokine release syndrome (CRS), including fatal or life-threatening reactions, occurred in patients following treatment with idecabtagene vicleucel. Do not administer idecabtagene vicleucel to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.Neurologic toxicities, which may be severe or life-threatening, occurred following treatment with idecabtagene vicleucel, including concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with idecabtagene vicleucel. Provide supportive care and/or corticosteroids as needed.Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) including fatal and life-threatening reactions, occurred in patients following treatment with idecabtagene vicleucel. HLH/MAS can occur with CRS or neurologic toxicities.Prolonged cytopenia with bleeding and infection, including fatal outcomes following stem cell transplantation for hematopoietic recovery, occurred following treatment with idecabtagene vicleucel.Idecabtagene vicleucel is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ABECMA REMS.

Serious side effects

Along with its needed effects, idecabtagene vicleucel may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking idecabtagene vicleucel:

More common

Less common

Other side effects

Some side effects of idecabtagene vicleucel may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to idecabtagene vicleucel: intravenous suspension.

Hematologic

Very common (10% or more): Neutropenia (96%), leukopenia (96%), lymphopenia (92%). Thrombocytopenia (63%), anemia (63%)[Ref]

Immunologic

Very common (10% or more): Cytokine release syndrome (CRS) (85%), viral infections (27%), bacterial infections (15%), hypogammaglobulinemia (e.g., blood immunoglobulin G decreased, hypogammaglobulinemia, hypoglobulinemia, laboratory IgG levels below 500 mg/dL) (21%), febrile neutropenia (16%), unspecified pathogen infections (15%)

Common (1% to 10%): Fungal infections, immunogenicity[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (e.g., arthralgia, back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, musculoskeletal stiffness, myalgia, neck pain, spinal pain) (45%), motor dysfunction (e.g., dysphonia, eyelid ptosis, hypotonia, motor dysfunction, muscle spasms, muscular weakness, restless legs syndrome) (11%)[Ref]

Ocular

Very common (10% or more): Dry eye (11%)[Ref]

Metabolic

Very common (10% or more): Hypophosphatemia (45%), anorexia (22%), weight decreased (13%), hyponatremia (10%), activated partial thromboplastin time (aPPT) increased (seconds) (10%)[Ref]

Psychiatric

Very common (10% or more): Insomnia/sleep deficit/sleep disorder (13%), nervousness/anxiety (12%)

Common (1% to 10%): Delirium[Ref]

Oncologic

Frequency not reported: Secondary malignancies[Ref]

Respiratory

Very common (10% or more): Upper respiratory tract infection (e.g., laryngitis, nasopharyngitis, pharyngeal erythema, pharyngitis, respiratory tract congestion, respiratory tract infection, rhinitis, rhinovirus infection, sinusitis, upper respiratory tract infection, upper respiratory tract infection bacterial) (34%), cough (e.g., cough, productive cough, upper-airway cough syndrome) (23%), hypoxia (20%), pneumonia (e.g., bronchopulmonary aspergillosis, lung infection, pneumonia, pneumonia aspiration, pneumonia cytomegaloviral, pneumonia pneumococcal, pneumonia pseudomonal) (17%), dyspnea (e.g., respiratory failure, dyspnea, dyspnea exertional, respiratory failure) (13%)[Ref]

Other

Very common (10% or more): Pyrexia (98%), chills (31%), edema (e.g., edema, face edema, fluid overload, fluid retention, generalized edema, peripheral edema, peripheral swelling, scrotal swelling, swelling) (25%), fatigue/asthenia/malaise (12%), chills (11%), general physical health deterioration (11%)[Ref]

General

The most common nonlaboratory adverse reactions (20% or greater) included CRS, infections - pathogen unspecified, fatigue, musculoskeletal pain, hypogammaglobulinemia, diarrhea, upper respiratory tract infection, nausea, viral infections, encephalopathy, edema, pyrexia, cough, headache, and decreased appetite.[Ref]

Nervous system

Very common (10% or more): CAR T cell-associated neurotoxicity (28%), encephalopathy (e.g., amnesia, bradyphrenia, cognitive disorder, confusional state, depressed level of consciousness, disturbance in attention, dyscalculia, dysgraphia, encephalopathy, lethargy, memory impairment, mental status changes, metabolic encephalopathy, somnolence, toxic encephalopathy) (26%), headache (23%), dizziness/presyncope/syncope/vertigo (17%), neuropathy peripheral (e.g., carpal tunnel syndrome, hypoesthesia, hypoesthesia oral, neuralgia, neuropathy peripheral, paresthesia, peripheral sensorimotor neuropathy, peripheral sensory neuropathy, sciatica) (17%), asterixis/tremor (10%)[Ref]

Renal

Very common (10% or more): Renal failure (e.g., acute kidney injury, blood creatinine increased, chronic kidney disease, renal failure, renal impairment) (10%)[Ref]

Cardiovascular

Very common (10% or more): Hypotension (e.g., hypotension, orthostatic hypotension) (41%), tachycardia/sinus tachycardia (35%), hypertension (11%)[Ref]

Dermatologic

Very common (10% or more): Rash (e.g., acne, dermatitis, dermatitis bullous, erythema, rash, rash macular, rash papular, urticaria) (14%), xerosis (e.g., dry eye, dry mouth, dry skin, lip dry, xerosis) (11%)[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (35%), nausea (29%), constipation (16%), vomiting (15%), oral pain (e.g., oral pain, oropharyngeal pain, toothache) (12%)[Ref]

References

1. Product Information. Abecma (idecabtagene vicleucel). Celgene Corporation. 2021.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.